Abstract: The embodiments of the present application disclose blockchain secure transaction methods and devices based on biomarker authentication. When a digital transaction voucher for the transaction between the payer and the payee is generated, the legality of the transaction is verified, instead of only using nonce, using the transaction key generated according to the biometric encrypted information of the payee user as the digital transaction voucher of the transaction. It can be guaranteed that the transaction will only occur between the payer and the payee designated by the payer due to the uniqueness of the biometric encrypted information. By the methods above, the legal identity information of the payer and payee to the transaction is authenticated from the perspective of the underlying blockchain information encryption, thereby ensuring that a digital transaction voucher can only be used once in a transaction and avoiding the problem of double spending.

Abstract: A method for protecting a software video player having Advanced Access Content System (AACS) includes reading segments of an encrypted first key from noncontiguous regions of memory, assembling the segments to form the encrypted first key, decrypting the encrypted first key with a second key to form a first key, extracting AACS key data from a pack file, decrypting the AACS key data to retrieve AACS Device Keys, generating an AACS Title Key using the AACS Device Key, clearing the AACS Device Keys and the first key from memory after the AACS Title Key is generated, decrying encrypted AACS content with the AACS Title Key to form AACS content, and displaying the AACS content.

Abstract: A method and a device for determining hydrophobic energy of protein are provided. The method for determining hydrophobic energy of the protein includes: based on space coordinates of the amino acids, determining distances of one amino acid to the remaining amino acids (S100); based on the distances, determining embedding coefficients of the amino acids (S200); and based on the embedding coefficients, determining the hydrophobic energy of the protein (S300).

Abstract: A method for protecting a software video player having Advanced Access Content System (AACS) includes reading segments of an encrypted first key from noncontiguous regions of memory, assembling the segments to form the encrypted first key, decrypting the encrypted first key with a second key to form a first key, extracting AACS key data from a pack file, decrypting the AACS key data to retrieve AACS Device Keys, generating an AACS Title Key using the AACS Device Key, clearing the AACS Device Keys and the first key from memory after the AACS Title Key is generated, decrying encrypted AACS content with the AACS Title Key to form AACS content, and displaying the AACS content.

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: where: R1 is a group represented by formula (A), (B) or (C); and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: 1

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: where: R1 is a group represented by formula (A), (B) or (C); and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: 1

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: where: R1 is a group represented by formula (A), (B) or (C);  and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods and their use as therapeutic agents.

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: 1

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: where: R1 is a group represented by formula (A), (B) or (C); and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: where: R1 is a group represented by formula (A), (B) or (C); and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.